Institution
Rio de Janeiro State University
Education•Rio de Janeiro, Brazil•
About: Rio de Janeiro State University is a education organization based out in Rio de Janeiro, Brazil. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 16631 authors who have published 30919 publications receiving 465753 citations. The organization is also known as: UERJ & Rio de Janeiro State University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The 4-yr CombAT data provide support for the long-term use of dutasteride and tamsulosin combination therapy in men with moderate-to-severe LUTS due to BPH and prostatic enlargement.
619 citations
••
21 Oct 2015-Nuclear Instruments & Methods in Physics Research Section A-accelerators Spectrometers Detectors and Associated Equipment
TL;DR: The Pierre Auger Observatory as mentioned in this paper, the world's largest cosmic ray observatory, has been in successful operation since completion in 2008 and has recorded data from an exposure exceeding 40,000 km$^2$ sr yr.
Abstract: The Pierre Auger Observatory, located on a vast, high plain in western Argentina, is the world's largest cosmic ray observatory. The objectives of the Observatory are to probe the origin and characteristics of cosmic rays above $10^{17}$ eV and to study the interactions of these, the most energetic particles observed in nature. The Auger design features an array of 1660 water-Cherenkov particle detector stations spread over 3000 km$^2$ overlooked by 24 air fluorescence telescopes. In addition, three high elevation fluorescence telescopes overlook a 23.5 km$^2$, 61 detector infill array. The Observatory has been in successful operation since completion in 2008 and has recorded data from an exposure exceeding 40,000 km$^2$ sr yr. This paper describes the design and performance of the detectors, related subsystems and infrastructure that make up the Auger Observatory.
615 citations
••
Istituto Giannina Gaslini1, Cincinnati Children's Hospital Medical Center2, University of Paris3, Semmelweis University4, Rambam Health Care Campus5, National Health Service6, Istanbul University7, University of Toronto8, Turkish Ministry of Health9, University of Geneva10, Charité11, Federal University of Rio de Janeiro12, University College London13, Katholieke Universiteit Leuven14, Rikshospitalet–Radiumhospitalet15, University of Paris-Sud16, Karolinska Institutet17, Hacettepe University18, Rio de Janeiro State University19, Novartis20, University of Genoa21
TL;DR: These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.
Abstract: A B S T R AC T BACKGROUND Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–interleukin-1β monoclonal antibody, in two trials. METHODS In trial 1, we randomly assigned patients, 2 to 19 years of age, with systemic JIA and active systemic features (fever; ≥2 active joints; C-reactive protein, >30 mg per liter; and glucocorticoid dose, ≤1.0 mg per kilogram of body weight per day), in a double-blind fashion, to a single subcutaneous dose of canakinumab (4 mg per kilo gram) or placebo. The primary outcome, termed adapted JIA ACR 30 response, was defined as improvement of 30% or more in at least three of the six core criteria for JIA, worsening of more than 30% in no more than one of the criteria, and resolution of fever. In trial 2, after 32 weeks of open-label treatment with canakinumab, pa tients who had a response and underwent glucocorticoid tapering were randomly assigned to continued treatment with canakinumab or to placebo. The primary outcome was time to flare of systemic JIA. RESULTS At day 15 in trial 1, more patients in the canakinumab group had an adapted JIA ACR 30 response (36 of 43 [84%], vs. 4 of 41 [10%] in the placebo group; P<0.001). In trial 2, among the 100 patients (of 177 in the open-label phase) who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinumab than among those who were switched to pla cebo (74% of patients in the canakinumab group had no flare, vs. 25% in the pla
611 citations
••
TL;DR: A new food classification which assigns foodstuffs according to the extent and purpose of the industrial processing applied to them is described, and the impact of the replacement of group 1 foods and group 2 ingredients by group 3 products on the overall quality of the diet, eating patterns and health is discussed.
Abstract: This paper describes a new food classification which assigns foodstuffs according to the extent and purpose of the industrial processing applied to them. Three main groups are defined: unprocessed or minimally processed foods (group 1), processed culinary and food industry ingredients (group 2), and ultra-processed food products (group 3). The use of this classification is illustrated by applying it to data collected in the Brazilian Household Budget Survey which was conducted in 2002/2003 through a probabilistic sample of 48,470 Brazilian households. The average daily food availability was 1,792 kcal/person being 42.5% from group 1 (mostly rice and beans and meat and milk), 37.5% from group 2 (mostly vegetable oils, sugar, and flours), and 20% from group 3 (mostly breads, biscuits, sweets, soft drinks, and sausages). The share of group 3 foods increased with income, and represented almost one third of all calories in higher income households. The impact of the replacement of group 1 foods and group 2 ingredients by group 3 products on the overall quality of the diet, eating patterns and health is discussed.
595 citations
••
TL;DR: In this paper, two-particle angular correlations for charged particles emitted in pPb collisions at a nucleon-nucleon center-of-mass energy of 5.02 TeV are presented.
575 citations
Authors
Showing all 16818 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hyun-Chul Kim | 176 | 4076 | 183227 |
Maria Elena Pol | 139 | 1414 | 99240 |
Wagner Carvalho | 135 | 1395 | 94184 |
Alberto Santoro | 135 | 1576 | 100629 |
Andre Sznajder | 134 | 1464 | 98242 |
Luiz Mundim | 133 | 1413 | 89792 |
Helio Nogima | 132 | 1274 | 84368 |
D. De Jesus Damiao | 128 | 1162 | 82707 |
Magdalena Malek | 128 | 598 | 67486 |
Sudha Ahuja | 127 | 1016 | 75739 |
Helena Malbouisson | 125 | 1151 | 82692 |
Jose Chinellato | 123 | 1116 | 64267 |
Flavia De Almeida Dias | 120 | 590 | 59083 |
Gilvan Alves | 119 | 829 | 69382 |
C. De Oliveira Martins | 119 | 880 | 66744 |